X

Trial Profile

A PHASE I STUDY OF RO7030816 IN PATIENTS WITH B-CELL NON-HODGKIN'S LYMPHOMA

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mosunetuzumab (Primary) ; Lenalidomide; Tocilizumab
Indications B-cell lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions; Pharmacokinetics; Registrational
Sponsors Chugai Pharmaceutical

Most Recent Events

09 Feb 2024 According to a Chugai Pharmaceutical media release, based on this phase I/II and phase I study conducted in Japan the company plans to apply for approval in Japan.
21 Dec 2021 Planned number of patients changed from 24 to 55.
21 Dec 2021 Planned End Date changed from 1 May 2020 to 30 Sep 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com